1048 related articles for article (PubMed ID: 26107752)
1. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
[TBL] [Abstract][Full Text] [Related]
2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
4. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
7. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Gaebel W; Schreiner A; Bergmans P; de Arce R; Rouillon F; Cordes J; Eriksson L; Smeraldi E
Neuropsychopharmacology; 2010 Nov; 35(12):2367-77. PubMed ID: 20686456
[TBL] [Abstract][Full Text] [Related]
8. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
[TBL] [Abstract][Full Text] [Related]
9. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
Green AI; Brunette MF; Dawson R; Buckley P; Wallace AE; Hafez H; Herz M; Narasimhan M; Noordsy DL; O'Keefe C; Sommi RW; Steinbook RM; Weeks M
J Clin Psychiatry; 2015 Oct; 76(10):1359-65. PubMed ID: 26302441
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning.
Nuechterlein KH; Ventura J; Subotnik KL; Gretchen-Doorly D; Turner LR; Casaus LR; Luo J; Boucher ML; Hayata JN; Bell MD; Medalia A
Psychol Med; 2022 Jun; 52(8):1517-1526. PubMed ID: 32981534
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
Dubois V; Peuskens J; Geerts P; Detraux J
Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
[TBL] [Abstract][Full Text] [Related]
14. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K
Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
16. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
Möller HJ
Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
[TBL] [Abstract][Full Text] [Related]
17. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
[TBL] [Abstract][Full Text] [Related]
19. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
Sárosi A
Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
[TBL] [Abstract][Full Text] [Related]
20. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
Lauriello J; McEvoy JP; Rodriguez S; Bossie CA; Lasser RA
Schizophr Res; 2005 Jan; 72(2-3):249-58. PubMed ID: 15560969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
